Start / Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation / 139 regulatory secrets revealed why your cmc strategy could make or break your biotech startup with rivka zaibel part 1

Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation

139: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 1

25 min • 25 mars 2025

In biotherapeutic drug development, the journey from discovery to clinic involves navigating a labyrinth of regulatory requirements and strategic considerations, particularly in Chemistry, Manufacturing, and Control (CMC).

In this episode of the Smart Biotech Scientist, host David Brühlmann engaged with Rivka Zaibel, President and Founder of ADRES - Advanced Regulatory Services Ltd. - to demystify the regulatory intricacies of biologics development and provide actionable insights for biotech leaders.

With over three decades of experience in the biopharmaceutical industry, Rivka Zaibel highlights that understanding the regulatory landscape is crucial for the success of biologics development.

Here are three key takeaways from this episode:

Prioritize CMC Development Early: CMC (Chemistry, Manufacturing, and Controls) development is crucial in biologics. Rivka emphasizes starting early and engaging with regulatory agencies to avoid costly delays and streamline the bioprocessing journey.
Understand Regulatory Differences: Different agencies (FDA vs. EMA) may have varied interpretations of guidelines. Familiarize yourself with ICH guidelines and the specific requirements of each agency to align your strategy effectively.
Leverage Existing Resources: Before developing your own product pathway, explore existing European Public Assessment Reports (EPARs) and summary bases of approval for comparable products. This research can provide valuable insights into regulatory expectations and streamline your approach.

For startups navigating the complexities of CMC development, Rivka highlights three critical quality and regulatory considerations essential for reaching Phase 1 trials. By embracing these key insights, biotech professionals can streamline the path to delivering innovative therapies to patients safely and efficiently.

In conclusion, as you continue your journey within the biopharmaceutical industry, let the Smart Biotech Scientist serve as your guide, demystifying the complexities and empowering you with the tools needed to thrive. Stay informed, stay proactive!

Connect with Rivka Zaibel:

LinkedIn: www.linkedin.com/in/rivka-zaibel/

ADRES - Advanced Regulatory Services Ltd.: www.adres.bio

Email: tanya@adres.bio

Next step:

Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

Senaste avsnitt

172: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 2

17 juli | 20 min

171: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 1

15 juli | 21 min

170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 2

10 juli | 23 min

169: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 1

8 juli | 26 min

168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 2

3 juli | 25 min

139: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 1

Senaste avsnitt

172: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 2

171: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 1

170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 2

169: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 1

168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 2

167: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 1

166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) - Part 2

165: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) - Part 1

164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf - Part 2

163: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf - Part 1

162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 2

161: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 1

160: The Ultimate Guide to Accelerating Perfusion Process Development Using 96-Deep-Well Plates with Tom Valentin - Part 2

159: The Ultimate Guide to Accelerating Perfusion Process Development Using 96-Deep-Well Plates with Tom Valentin - Part 1

158: How to Detect Endotoxins Without Bleeding a Single Horseshoe Crab with Anika Hoffmann - Part 2

157: How to Detect Endotoxins Without Bleeding a Single Horseshoe Crab with Anika Hoffmann - Part 1

156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook

155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything

154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos - Part 2

153: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos - Part 1

152: Is an Indian CDMO the Right Move for Your Biologics Pipeline? with Abdelaziz Toumi - Part 2

151: Is an Indian CDMO the Right Move for Your Biologics Pipeline? with Abdelaziz Toumi - Part 1

150: How to Leverage AI in Media Development Without Sacrificing Process Understanding with Tom Fletcher - Part 2

149: How to Leverage AI in Media Development Without Sacrificing Process Understanding with Tom Fletcher - Part 1

148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir - Part 2

147: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir - Part 1

146: Beyond ELISA: The 10-Minute Immunoassay Enabling Real-Time Bioprocess Control with Bruno Oesch - Part 2

145: Beyond ELISA: The 10-Minute Immunoassay Enabling Real-Time Bioprocess Control with Bruno Oesch - Part 1

144: The Future of Biotech: Making Biotherapeutics More Accessible Faster

143: Bioprocess Breakthroughs: How Smart Bioprocessing Is Democratizing Life-Saving Treatments

142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor - Part 2

141: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor - Part 1

140: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 2

139: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 1

138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 2

137: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 1

136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)

135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All

134: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 2

133: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 1

132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani - Part 2

131: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani - Part 1

130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 2

129: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 1

128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 2

127: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 1

126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 2

125: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 1

124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 2

123: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 1

122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 2

121: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 1

120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 2

119: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 1

118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough - Part 2

117: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough - Part 1

116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 2

115: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 1

114: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 2

113: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 1

112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 2

111: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 1

110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 2

109: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 1

108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 2

107: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 1

106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 2

105: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 1

104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 2

103: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 1

102: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 2

101: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 1

100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 2

99: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 1

98: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 2

97: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 1

96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 2

95: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 1